Diabetes, obesity & metabolism

Keyphrases

Publications

volume 25, number 4, 2023

Ji Hee Yu, Regina E Y Kim, So Young Park, Da Young Lee, Hyun Joo Cho, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Chol Shin, Nan Hee Kim
Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism 25 (4) (2023)
Mojca Jensterle Sever, Simona Ferjan, Luka Ležaič, Aljaž Sočan, Katja Goričar, Katja Zaletel, Andrej Janez
Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, obesity & metabolism 25 (4) (2023)
Paolo Sbraccia, Jens Aberle, Anne Helene Olsen, Naveen Rathor, Atheline Major-Pedersen
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. Diabetes, obesity & metabolism 25 (4) (2023)
Ulagamadesan Venkatesan, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Jean-Claude Tardif, Marc A Pfeffer
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial. Diabetes, obesity & metabolism 25 (4) (2023)
Mojca Jensterle Sever, Simona Ferjan, Luka Ležaič, Aljaž Sočan, Katja Goričar, Katja Zaletel, Andrej Janez
Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence. Diabetes, obesity & metabolism 25 (4) (2023)
Ji Hee Yu, Regina E Y Kim, So Young Park, Da Young Lee, Hyun Joo Cho, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Chol Shin, Nan Hee Kim
Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
John S Pemberton, Emma G Wilmot, Katharine Barnard-Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, obesity & metabolism 25 (4) (2023)
Ulagamadesan Venkatesan, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Jean-Claude Tardif, Marc A Pfeffer
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial. Diabetes, obesity & metabolism 25 (4) (2023)
Raul C Camacho, David C Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz Lubomirski, Traymon Beavers, Javier Cabrera, Peggy Wong, Andrea R Nawrocki
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions. Diabetes, obesity & metabolism 25 (4) (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Paolo Sbraccia, Jens Aberle, Anne Helene Olsen, Naveen Rathor, Atheline Major-Pedersen
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. Diabetes, obesity & metabolism 25 (4) (2023)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Raul C Camacho, David C Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz Lubomirski, Traymon Beavers, Javier Cabrera, Peggy Wong, Andrea R Nawrocki
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions. Diabetes, obesity & metabolism 25 (4) (2023)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Àngels Molló, Bogdan Vlacho, Mònica Gratacòs, Manel Mata-Cases, Esther Rubinat, Anna Berenguera, Jordi Real, Ramon Puig-Treserra, Xavier Cos, Josep Franch-Nadal, Kamlesh Khunti F MedSci, Esmeralda Castelblanco, null null
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel, Christoph Kapitza, Daniela Lamers, Claus Thamer, Corinna Schölch, Michael Desch, Anita M Hennige
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Mojca Jensterle Sever, Simona Ferjan, Luka Ležaič, Aljaž Sočan, Katja Goričar, Katja Zaletel, Andrej Janez
Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, obesity & metabolism 25 (4) (2023)
Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence. Diabetes, obesity & metabolism 25 (4) (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Arihiro Kiyosue, Julia P Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J Heine
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Leona Plum-Mörschel, Eric Zijlstra
Oral insulin: A history of ambition, failure and data torturing. Diabetes, obesity & metabolism 25 (4) (2023)
Ronnie Aronson, Ruth E Brown, Lisa Chu, Harpreet S Bajaj, Hasnain Khandwala, Alexander Abitbol, Nadia Malakieh, Ronald Goldenberg
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, obesity & metabolism 25 (4) (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Raul C Camacho, David C Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz Lubomirski, Traymon Beavers, Javier Cabrera, Peggy Wong, Andrea R Nawrocki
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions. Diabetes, obesity & metabolism 25 (4) (2023)
Àngels Molló, Bogdan Vlacho, Mònica Gratacòs, Manel Mata-Cases, Esther Rubinat, Anna Berenguera, Jordi Real, Ramon Puig-Treserra, Xavier Cos, Josep Franch-Nadal, Kamlesh Khunti F MedSci, Esmeralda Castelblanco, null null
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study. Diabetes, obesity & metabolism 25 (4) (2023)
YipHan Chin, Jieyu Lim, Gwyneth Kong, Cheng Han Ng, Rachel Goh, Mark Dhinesh Muthiah, Anurag Mehta, Bryan Chong, Chaoxing Lin, Kai En Chan, William Kong, Kian Keong Poh, Roger Foo, Ping Chai, Tiong-Cheng Yeo, Adrian F Low, Chi Hang Lee, Huay Cheem Tan, Mark Yan-Yee Chan, A Mark Richards, Poay-Huan Loh, Nicholas W S Chew
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes, obesity & metabolism 25 (4) (2023)
Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence. Diabetes, obesity & metabolism 25 (4) (2023)
Ulagamadesan Venkatesan, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Jean-Claude Tardif, Marc A Pfeffer
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial. Diabetes, obesity & metabolism 25 (4) (2023)
Jesper Hallas, Jacob Harbo Andersen, Jens Soendergaard, Reimar Wernich Thomsen, Tina Vilsbøll
Changes in the use of glucose-lowering drugs: A Danish nationwide study. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Àngels Molló, Bogdan Vlacho, Mònica Gratacòs, Manel Mata-Cases, Esther Rubinat, Anna Berenguera, Jordi Real, Ramon Puig-Treserra, Xavier Cos, Josep Franch-Nadal, Kamlesh Khunti F MedSci, Esmeralda Castelblanco, null null
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study. Diabetes, obesity & metabolism 25 (4) (2023)
YipHan Chin, Jieyu Lim, Gwyneth Kong, Cheng Han Ng, Rachel Goh, Mark Dhinesh Muthiah, Anurag Mehta, Bryan Chong, Chaoxing Lin, Kai En Chan, William Kong, Kian Keong Poh, Roger Foo, Ping Chai, Tiong-Cheng Yeo, Adrian F Low, Chi Hang Lee, Huay Cheem Tan, Mark Yan-Yee Chan, A Mark Richards, Poay-Huan Loh, Nicholas W S Chew
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes, obesity & metabolism 25 (4) (2023)
John S Pemberton, Emma G Wilmot, Katharine Barnard-Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, obesity & metabolism 25 (4) (2023)
Ji Hee Yu, Regina E Y Kim, So Young Park, Da Young Lee, Hyun Joo Cho, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Chol Shin, Nan Hee Kim
Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study. Diabetes, obesity & metabolism 25 (4) (2023)
YipHan Chin, Jieyu Lim, Gwyneth Kong, Cheng Han Ng, Rachel Goh, Mark Dhinesh Muthiah, Anurag Mehta, Bryan Chong, Chaoxing Lin, Kai En Chan, William Kong, Kian Keong Poh, Roger Foo, Ping Chai, Tiong-Cheng Yeo, Adrian F Low, Chi Hang Lee, Huay Cheem Tan, Mark Yan-Yee Chan, A Mark Richards, Poay-Huan Loh, Nicholas W S Chew
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes, obesity & metabolism 25 (4) (2023)
John S Pemberton, Emma G Wilmot, Katharine Barnard-Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Paolo Sbraccia, Jens Aberle, Anne Helene Olsen, Naveen Rathor, Atheline Major-Pedersen
Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. Diabetes, obesity & metabolism 25 (4) (2023)